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Abstract: The prognosis for patients with newly diagnosed malignant gliomas remains 
poor; however there have been some recent advances in treatment that have generated opti-
mism. Medical management usually includes administration of corticosteroids to control 
peritumoral edema. Anticonvulsants are indicated for patients with established tumor-related 
seizures; however, the prophylactic use of anticonvulsants remains controversial. Advances 
in neurosurgical techniques have improved the safety of tumor resection and most patients 
undergo the maximal safe surgical debulking of tumor. The tissue sample obtained provides 
conclusive pathologic diagnosis and tumor classiﬁ  cation and extensive tumor resection may 
impact patient outcome. For glioblastoma, external beam radiation had been the conventional 
ﬁ  rst line treatment; however a recent international phase III trial has provided level 1 evidence 
that a chemoradiation regimen using external beam radiation plus the oral chemotherapy agent 
temozolomide provides a survival advantage over radiation alone. Correlative studies were also 
performed that demonstrated better outcomes for patients with tumors demonstrating methyla-
tion (inactivation) of the promoter region of methyl guanine methyltransferase (MGMT) gene. 
Additional studies are in progress building on the clinical trial results using different dosing 
schedules of temozolomide and combination regimens. Studies are also underway to develop 
molecular markers, such as expression of MGMT that may help select the patients most likely 
to beneﬁ  t from this treatment.
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Although the prognosis for patients with newly diagnosed malignant gliomas remains 
poor, recent advances in the treatment of these cancers have resulted in an incremental 
improvement in survival. More importantly, this progress has spawned renewed inter-
est and enthusiasm for investigating new treatments, translating laboratory ﬁ  ndings 
into new therapeutic approaches and optimizing the treatment of individual patients 
based on molecular characterization of the tumor. This article will review these recent 
advances.
The incidence of malignant gliomas in the United States has been estimated to 
be approximately 18,500 cases per year (CBTRUS 2005). The median age of these 
patients is in the mid-40s, although the more malignant tumors are more prevalent in 
older patients. The treatment of patients with malignant brain tumors has proven to 
be quite challenging. In addition to the typical patient management issues related to 
treatment toxicities such as myelotoxicity, nausea and vomiting, patients with brain 
tumors are at risk of seizures and have a high incidence of both deep venous thrombosis 
and pulmonary embolism (Marras et al 2000; Hildebrand et al 2005). In evaluating 
possible treatment regimens, patient clinical characteristics are important determinants Therapeutics and Clinical Risk Management 2007:3(6) 1028
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of outcome and selection criteria may alter apparent treatment 
efﬁ  cacy (Curran et al 1993). Many studies identify prognostic 
factors such as age and performance status, although tumor 
grade is the most important determinant of prognosis. There-
fore, treatments that change the standard of care generally 
are large, randomized clinical trials or studies that carefully 
account for the potential of selection bias by performing 
appropriate comparisons with adjusted historical data.
Although the treatment of malignant gliomas is evolving, 
several fundamental principles of patient management 
remain. At time of presentation, most patients require treat-
ment with corticosteroids because of peritumoral edema and 
resultant mass effect (Moots 1998). Because of the potential 
for long-term complications of corticosteroids, the lowest 
therapeutic dose should be used. Individual variation in the 
required dose will occur, but most often dexamethasone in 
doses ranging from 4–16 mg per day is required. Patients who 
present with seizures do require treatment with anticonvul-
sants. The choice of anticonvulsant can be complex and may 
be dictated by availability of a parenteral form, particularly 
if emergency treatment of the seizures is required. The ﬁ  rst 
generation anticonvulsants such as phenytoin, phenobarbital 
and carbamazepine will augment hepatic cytochrome P450 
enzyme activity (Fetell et al 1997). This enzyme enhancement 
has been shown to alter the pharmacokinetics of many cancer 
chemotherapy agents. For this reason, many patients with 
brain tumors are treated with the newer generation anticon-
vulsants such as levitiracetam, gabapentin, or lamotrigene. 
The prophylactic use of anticonvulsants in patients with brain 
tumors who have not had a seizure remains controversial. 
The American Academy of Neurology published a consensus 
paper in 2000, which after performing a meta-analysis of 
available phase III studies of prophylactic anticonvulsant use 
in brain tumor patients concluded that there was insufﬁ  cient 
data to support use in patients who had not had a document 
seizure (Glantz et al 2000).
Patients may present with both slowly evolving signs and 
symptoms such as progressive memory loss or hemiparesis 
or abruptly with seizures or rapid loss of neurologic function 
(often as a consequence of intra-tumoral hemorrhage). Brain 
imaging with either magnetic resonance imaging (MRI) or 
computerized axial tomography (CAT) scans will reveal the 
tumor (Wen et al 2001). If no contraindication exists, MRI 
is the diagnostic test of choice, as this imaging modality 
provides better deﬁ  nition of tumor and neuroanatomy. At 
this point, a histopathologic diagnosis must be made. The 
decision to resect tumor or perform an open or stereotactic 
biopsy is usually based on tumor location, need for tumor 
decompression because of increased intracranial pressure or 
conversely comorbid conditions in the patient that increases 
the risk of an extensive surgical procedure. Only patients 
with inﬁ  ltrating brainstem abnormalities are treated with-
out histologic conﬁ  rmation of tumor because of the risk of 
neurologic injury from the surgical procedure. In these situa-
tions, other processes such as multiple sclerosis, sarcoidosis 
or Lyme disease must be excluded before initiating brain 
tumor treatment.
The therapeutic role of surgery remains controversial. 
There have been no randomized studies comparing biopsy 
with tumor resection in patients with malignant gliomas. 
Statistical analyses of large clinical trials often uncover extent 
of tumor resection as a prognostic factor. However, other 
factors such as tumor location, concurrent medical illness 
and patient performance status may impact the decision for 
surgery and the resultant impact of surgical resection may 
reﬂ  ect a selection bias. Some carefully evaluated retrospec-
tive series do provide some supportive evidence that surgical 
resection may improve outcomes. The study by LaCroix 
evaluated 417 consecutive patients with malignant gliomas 
who underwent tumor resection with the pre-operative intent 
to perform a complete resection (Lacroix et al 2001). After 
accounting for prognostic factors such as age and perfor-
mance status, they found that patients who had undergone 
at least a 98 percent resection by volumetric analysis had 
a statistically signiﬁ  cant improvement in overall survival 
(13 vs 8.8 months, p < 0.0001).
Most patients require treatment with radiation therapy. 
Studies from the late 1970s and early 1980s conﬁ  rm the 
beneﬁ  t of external beam radiation over surgery and sup-
portive care with steroids alone (Walker et al 1978; Walker 
et al 1980). Early studies used either whole brain radiation 
or regional ﬁ  elds. Although proven effective, these methods 
did increase the incidence of late radiation-induced brain 
injury (Vick and Paleologos 1995). Newer technologies 
such as conformal ﬁ  elds with 3-dimentional planning and 
intensity-modulated radiation therapy (IMRT) delivers the 
desired dose of radiation to the target, but limits exposure 
to the surrounding normal brain parenchyma (reviewed in 
(Mehta and Silverberg 2005).
The role of chemotherapy for the treatment of malig-
nant brain tumors has been less well deﬁ  ned. Despite a 
large number of clinical trials reported over the last 30 
years, there has been very little evidence that the addition 
of chemotherapy signiﬁ  cantly impacts survival in this 
patient population when combined with surgery and radia-
tion therapy. The seminal studies performed by the Brain Therapeutics and Clinical Risk Management 2007:3(6) 1029
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Tumor Study Group in the 1970s clearly demonstrated the 
survival beneﬁ  t of radiation compared with supportive care.
In these randomized trials, the addition of a nitrosourea, 
either carmustine (BCNU) or semustine (CCNU) did not 
signiﬁ  cantly improve survival (Walker et al 1980; Green 
et al 1983). However, a meta-analysis performed in 1991 
suggested that the addition of chemotherapy to radiation 
may have a modest impact, improving survival at 1 year 
by 10% (Fine et al 1993). A more extensive meta-analysis 
published in 2001 extended these ﬁ  ndings (Stewart 2002). 
This study by Stewart and colleagues collected individual 
patient data from 12 randomized trials that compared 
radiation with a radiation and chemotherapy combina-
tion in patients with malignant gliomas. Their analysis 
revealed a statistically signiﬁ  cant but modest improvement 
in survival at one year of 6 percent. The Medical Research 
Council (MRC) in the United Kingdom performed a large 
randomized trial comparing radiation therapy alone with 
radiation treatment followed by adjuvant treatment with 
PCV (procarbazine, CCNU and vincristine) (MRC 2001). 
Despite enrolling 673 patients, no difference was detected 
in survival between the two groups. Therefore, on the basis 
of these studies, the beneﬁ  t of chemotherapy for treating 
malignant gliomas remained unproven.
The introduction of temozolomide
In 1992, a research group at the MRC reported on the initial 
clinical testing of temozolomide, an imidazotetrazine deriva-
tive that is hydrolyzed at neutral pH to the active drug mono-
methyl 5-triazeno imidazole carboxamide (MTIC) (Newlands 
et al 1992). They reported excellent oral bioavailability and 
the initial phase I testing evaluated a single day regimen as 
well as a 5-consective day regimen. Experimental studies 
supported prolonged dosing, therefore, the 5 day regimen 
which was then established as the preferred treatment 
schedule and a maximum tolerated dose of 200 mg/m2 was 
determined. Pharmacokinetic studies demonstrated excellent 
oral bioavailability with nearly 100% absorption in fasting 
patients. Further testing revealed no signiﬁ  cant alterations 
with hepatic cytochrome P450 enzyme inducers such as the 
early generation anticonvulsants. The early clinical testing 
demonstrated activity in glial malignancies, supporting the 
further development of this agent for primary central nervous 
system cancers (O’Reilly et al 1993). The toxicity proﬁ  le 
from these early studies showed a low incidence of myelo-
toxicity that was not cumulative. Nausea and vomiting was 
generally easily controlled with antiemetics and constipation 
was the most frequently reported toxicity.
Subsequently, several clinical trials were performed. 
Two of the early studies markedly impacted the use of 
temozolomide. The ﬁ  rst was a randomized phase II clinical 
trial comparing temozolomide with procarbazine in patients 
with recurrent glioblastoma (WHO Grade IV) (Yung et al 
2000). Procarbazine, an oral agent, was considered an estab-
lished treatment for recurrent malignant gliomas. The study 
randomized a total of 225 patients. The objective response 
rates were similar between the two treatments (5.4% for 
temozolomide and 5.3% for procarbazine). However, the 
6-month progression free survival rate was signiﬁ  cantly 
improved for patients on the temozolomide arm (21 vs 8%, 
p = 0.008) and additional quality of life testing using the 
EORTC QOL battery strongly favored temozolomide 
(Macdonald et al 2005). However, the primary endpoint of 
the study, objective response, did not demonstrate an advan-
tage for temozolomide in this population and FDA approval 
for recurrent glioblastoma was denied.
At the same time, an open label, single arm phase II study 
was performed in patients with recurrent anaplastic glioma 
(WHO Grade III) (Yung et al 1999). Eligibility criteria 
included prior treatment with radiation therapy and some 
patients did under adjuvant treatment with a nitrosourea 
containing regimen, either PCV or a nitrosourea alone. This 
study accrued 162 patients, however on central neuropathol-
ogy review only 111 patients were found to have a grade III 
glioma. Overall objective response rate (complete or partial 
response) for the entire patient group was 35%, the same as 
the response rate for the conﬁ  rmed grade III tumors (111 of 
the 162 enrolled patients). The objective response rate for the 
subset of patients with grade III tumors and a prior history of 
nitrosourea use was 22%. On the basis of the response rate 
in previously treated patients, temozolomide received FDA 
approval for use in patients with grade III gliomas who had 
failed prior nitrosourea treatment.
Temozolomide use in newly 
diagnosed high-grade gliomas
Temozolomide has been tested in several clinical trials in 
patients with high grade gliomas after a surgical procedure 
to establish the diagnosis, but before the initiation of radia-
tion therapy (often referred to as neoadjuvant treatment). 
The study by Gilbert et al (2002) treated 57 patients with 
either glioblastoma or anaplastic astrocytoma with up to 
4 cycles of temozolomide (5 day out of 28 day cycle) prior 
to radiation(Gilbert et al 2002). The objective response 
rate to the chemotherapy component was 42% for glioblas-
toma and 34% for AA. However, the responses were often Therapeutics and Clinical Risk Management 2007:3(6) 1030
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not durable and the overall median survival of GBM and 
AA at 13.2 and 23.5 months respectively did not suggest 
an improvement over other radiation and chemotherapy 
regimens. Similarly, Chibbaro and colleagues (2004) treated 
42 patients with GBM, AA or anaplastic oligodendroglioma 
(AO) with pre-radiation chemotherapy. They report a 40% 
objective response rate, but an overall median survival of 
14.1 months, despite including the Grade III tumors with 
an overall better prognosis. The study by Brada et al (2005) 
treated 187 patients with pre-radiation temozolomide. 
A maximum of 2 cycles were administered and a response 
rate of 20% was reported. Finally, Balana et al (2004) exam-
ined the efﬁ  cacy of combining temozolomide with cisplatin 
as the initial treatment for patients with GBM. Forty patients 
underwent up to 3 cycles of the combination chemotherapy 
followed by conventional external beam radiation. Objective 
responses were reported in 45% of patients to the chemo-
therapy component, however the overall median survival 
was only 12.5 months. These studies conﬁ  rm the activity of 
temozolomide in terms of response. However, neoadjuvant 
use did not demonstrate an overall survival beneﬁ  t.
Phase II study of concurrent 
temozolomide and radiation 
followed by adjuvant temozolomide
A novel treatment regimen was published by Stupp and 
colleagues in 2002 (Stupp et al 2002). They performed a 
phase II study in patients with newly diagnosed glioblas-
toma. Patients received conventional external beam radiation 
therapy, a total dose of 60 Gy, with the concurrent administra-
tion of temozolomide at 75 mg/m2. The radiation treatment 
was administered 5 days per week, whereas the temozolo-
mide was administered all 7 days. Therefore patients received 
a minimum of 42 consecutive days of temozolomide. One 
month after the completion of the chemoradiation, patients 
began adjuvant temozolomide using the conventional 
schedule of 150–200 mg/m2 days 1–5 of a 28 day cycle for 
a maximum of 6 cycles. A total of 62 patients were accrued 
and the median survival of 16.2 months looked promising. 
The possibility of inadvertent selection bias was addressed 
by comparing these results with the Radiation Therapy 
Oncology Group (RTOG) recursive partitioning database. 
In each class (III, IV , V), the patients on the new protocol 
showed a superior survival.
Subsequent studies have supported these phase II data. 
The trial performed by Combs et al treated 53 patients with 
GBM using a chemoradiation regimen consisting of 60 Gy 
of radiation delivered as 2 Gy fractions along with daily 
temozolomide at 50 mg/m2 (compared with the 75 mg/m2 
dosing used by Stupp) (Combs et al 2005). No post-radiation 
chemotherapy was administered. Estimated median survival 
was reported to be 19 months. The chemoradiation regimen 
developed by Stupp et al described above was compared 
with conventional external beam radiation in a randomized 
phase II, reported by Athanassiou et al (Athanassiou et al 
2005). A total of 130 patients with histologically conﬁ  rmed 
GBM were randomized. Median survival was better in the 
experimental arm compared with the control (radiation only) 
group, (13.4 vs 7.7 months respectively).
Phase III trial comparing 
chemoradiation with radiation alone 
for newly diagnosed glioblastoma
The results reported by Stupp et al (2004), outlined above, 
supported the need for a phase III trial to conﬁ  rm the beneﬁ  t 
of chemoradiation over radiation alone for patients with 
newly diagnosed GBM. The EORTC and the NCI-Canada 
collaborated on this large trial. A total of 573 patients were 
accrued from August 2000 until March 2002. These patients 
were randomized to radiation only (286 patients) or the 
radiotherapy plus temozolomide regimen (287 patients), as 
shown in the Schema in Figure 1. The two groups were well 
balanced by demographic and prognostic characteristics at 
time of study entry. The majority of patients received the full 
dose of radiation (92% in radiation arm, 95% in chemora-
diation arm); the full concurrent temozolomide course was 
administered to 87% of the patients. Adjuvant temozolomide 
was initiated in 78% of patients with a median of 3 cycles (out 
of 6 planned) administered. Disease progression was the most 
common reason for treatment discontinuation (39%).
The study demonstrated a clear survival benefit for 
patients treated with the chemoradiation regimen compared 
with radiation alone. The median overall survival was 14.6 
months for patients treated with chemoradiation compared 
with 12.1 months for patients treated with radiation therapy 
alone (p < 0.001 by log rank test). Additionally, the 2-year 
survival rate was also signiﬁ  cantly greater in the chemoradia-
tion group compared with the radiation alone treatment arm 
(26% vs. 10%). The differences in survival persisted despite 
the fact that at time of disease progression, 161 of 282 patients 
(57%) in the radiation only arm received salvage treatment 
with temozolomide. Only 60 of 277 patients (22%) on the 
chemoradiation arm received additional temozolomide at 
disease progression. The chemoradiation treatment regimen 
was well-tolerated. Early discontinuation from severe 
myelotoxicity occurred in only 5% of patients. This study Therapeutics and Clinical Risk Management 2007:3(6) 1031
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provided Level 1 evidence that the chemoradiation regimen 
is superior to radiation treatment alone and has established 
this treatment as the standard of care for patients with newly 
diagnosed GBM. Furthermore, the FDA analyzed these data 
and full approval was given for temozolomide in patients 
with newly diagnosed GBM (Cohen et al 2005). The current 
standard approach is radiation therapy with concurrent daily 
temozolomide at a dose of 75mg/m2. During the course 
of this therapy, prophylaxis against pneumocystis carinii 
pneumonia (PCP) is recommended. Adjuvant temozolomide 
is then started three to four weeks after the completion of 
the concurrent therapy. The daily dose of temozolomide is 
150mg/m2 of days 1–5 of a 28-day cycle for the ﬁ  rst course, 
and if tolerated the dose is escalated to 200mg/m2 daily for 
the ﬁ  ve days every 28 days. This therapy is continued for 
at least six months in patients with no evidence of disease 
progression or severe treatment-related toxicity.
Methylguanine methyltransferase 
(MGMT) analysis
A laboratory correlative study was performed by Hegi and 
colleagues (2005) using tissue specimens from patients 
enrolled on the EORTC/NCI-C trial described above. 
These investigators hypothesized that tumors with hyper-
methylation (inactivation) of the methylguanine methyl-
transferase (MGMT) gene would have a better prognosis 
that those patients with only unmethylated, therefore active 
expression of the MGMT gene. Prior studies had identiﬁ  ed 
MGMT expression as a potential mechanism of resistance 
to alkylating agent chemotherapy including temozolomide. 
Of the 573 patients enrolled, they were able to determine 
the methylation status of the MGMT gene in 203 samples 
using a methylation-speciﬁ  c polymerase chair reaction (PCR) 
technique. Correlation of methylation status of the MGMT 
gene promoter region with survival revealed that patients 
with tumors containing methylated MGMT promoter had 
a far better prognosis than those with only unmethylated 
promoter as measured by median survival (18.2 months vs 
12.2 months). The two-year survival rate was also higher in 
the patients with tumors demonstrating methylated MGMT 
promoter (46% vs 10%). Amongst patients with methylated 
MGMT promoter, patients treated with the chemoradiation 
regimen fared better than those treated with radiation alone 
(median survival 21.7 months vs 15.3 months, respectively). 
These data support the potential prognostic and treatment 
predictive importance of the methylation status of the MGMT 
gene promoter region. However, these retrospective data 
require prospective validation.
Ongoing studies and future 
directions
The results of the collaborative efforts of the EORTC 
and NCI-C along with the compelling correlative data 
from the MGMT gene promoter methylation data has 
Figure 1 Schema for the phase III randomized trial.Therapeutics and Clinical Risk Management 2007:3(6) 1032
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generated widespread interest in developing new treatment 
regimens building on this foundation. A clinical trial was 
recently launched that represents the collaborative efforts 
of colleagues from the RTOG and the EORTC that was 
designed to address the question whether increasing the 
dose-intensity of the temozolomide will impact efﬁ  cacy. 
Preliminary data suggest that prolonged dosing (up to 21 
days) of temozolomide will signiﬁ  cantly reduce MGMT 
activity in peripheral blood mononuclear cells (Tolcher et al 
2003). Furthermore, a phase II clinical trial using a 7 day on, 
7 day off regimen of temozolomide in patients with recurrent 
GBM demonstrated a high response rate with 6 month PFS 
of 46% (Wick et al 2004).
RTOG/EORTC protocol 0525, as outlined in Figure 2, 
will randomize patients after standard concurrent chemora-
diation to either standard dose adjuvant temozolomide or a 
dose-intense regimen of 21 out of 28 day dosing per cycle. 
Patients will be stratiﬁ  ed for the randomization by clinical 
prognostic factors (using the RTOG Recursive Partitioning 
System) and MGMT gene promoter methylation status. A 
total accrual of 1154 patients is required, but the study will 
attempt to validate the prognostic and predictive ability of 
the MGMT analysis and determine if dose-intense treatment 
improves the outcome for patients with “resistant” tumors by 
modulating tumor MGMT activity using the prolonged dosing 
schedule. Additionally, net clinical beneﬁ  t will be measured 
using validated instruments to measure symptom burden, 
quality of life, and neurocognitive function.
Conclusion
The treatment of malignant primary brain tumors, particularly 
glioblastoma, remains challenging. In addition to the inherent 
refractory nature of these cancers, issues such as loss of 
neurologic function complicate care. The introduction of 
temozolomide represents a signiﬁ  cant advance in treatment. 
Temozolomide has both excellent oral bioavailability and 
lack of signiﬁ  cant cumulative myelotoxicity which permits 
testing of novel and prolonged dosing schedules. These 
characteristics allowed the development of the concurrent use 
of temozolomide with external beam radiation followed by 
adjuvant temozolomide treatment. This regimen has proven to 
be better than radiation alone and is now the standard of care 
for patients with newly diagnosed GBM. A recently launched 
trial is evaluating a new, more intensive schedule to determine 
if this beneﬁ  t of temozolomide can be enhanced.
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